Verrica Pharmaceuticals Inc (VRCA)

$0.68 +0.04 (5.80%)
Market Cap 30.89M
Revenue (ttm) 5.12M
Net Income (ttm) -67.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,308.59%
Debt to Equity Ratio -3.21
Volume 181,700
Avg Vol 803,496
Day's Range N/A - N/A
Shares Out 45.60M
Stochastic %K 41%
Beta 1.49
Analysts Sell
Price Target $3.33

Latest News on VRCA

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 9, 2024, 4:15 PM EST - 5 weeks ago

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Dec 6, 2024, 8:00 AM EST - 6 weeks ago

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Verrica Announces Pricing of $42.0 Million Public Offering

Nov 21, 2024, 7:30 AM EST - 2 months ago

Verrica Announces Pricing of $42.0 Million Public Offering

Verrica Announces Proposed Public Offering

Nov 20, 2024, 4:05 PM EST - 2 months ago

Verrica Announces Proposed Public Offering

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Oct 30, 2024, 10:00 AM EDT - 2 months ago

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

Oct 24, 2024, 7:00 AM EDT - 3 months ago

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Oct 11, 2024, 5:21 PM EDT - 3 months ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

Oct 2, 2024, 7:30 AM EDT - 3 months ago

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Sep 27, 2024, 10:29 PM EDT - 4 months ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

Sep 4, 2024, 7:30 AM EDT - 4 months ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:37 PM EDT - 5 months ago

Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 7:45 AM EDT - 5 months ago

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

Aug 14, 2024, 7:30 AM EDT - 5 months ago

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

Aug 6, 2024, 7:30 AM EDT - 5 months ago

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

Jul 1, 2024, 7:30 AM EDT - 7 months ago

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 30, 2024, 4:30 PM EDT - 8 months ago

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

May 15, 2024, 7:30 AM EDT - 8 months ago

Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2024 Earnings Call Transcript

May 13, 2024, 11:49 AM EDT - 8 months ago

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2024 Earnings Call Transcript

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

May 13, 2024, 7:30 AM EDT - 8 months ago

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

May 9, 2024, 7:30 AM EDT - 9 months ago

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

May 8, 2024, 7:30 AM EDT - 9 months ago

Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 7:30 AM EDT - 10 months ago

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

Mar 26, 2024, 7:30 AM EDT - 10 months ago

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 12:22 PM EST - 11 months ago

Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 29, 2024, 7:30 AM EST - 11 months ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

Feb 27, 2024, 7:30 AM EST - 11 months ago

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

Feb 22, 2024, 7:30 AM EST - 11 months ago

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition

Feb 5, 2024, 7:30 AM EST - 1 year ago

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

Jan 29, 2024, 7:30 AM EST - 1 year ago

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Jan 5, 2024, 7:30 AM EST - 1 year ago

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts

Jan 4, 2024, 7:30 AM EST - 1 year ago

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts

Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

Jan 3, 2024, 7:30 AM EST - 1 year ago

Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

Verrica Pharmaceuticals' Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan

Dec 15, 2023, 6:00 AM EST - 1 year ago

Verrica Pharmaceuticals' Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan

Verrica Pharmaceuticals Inc. (VRCA) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 9:57 AM EST - 1 year ago

Verrica Pharmaceuticals Inc. (VRCA) Q3 2023 Earnings Call Transcript

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 7:30 AM EST - 1 year ago

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

Oct 25, 2023, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

Sep 27, 2023, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises

Aug 24, 2023, 8:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises

Verrica Issues Statement in Support of FDA's Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum

Aug 23, 2023, 7:30 AM EDT - 1 year ago

Verrica Issues Statement in Support of FDA's Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting

Aug 10, 2023, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

Aug 8, 2023, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association's (AAD) 2023 Innovation Academy Meeting

Aug 3, 2023, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association's (AAD) 2023 Innovation Academy Meeting

Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed

Jul 26, 2023, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed

Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET

Jul 24, 2023, 7:00 AM EDT - 1 year ago

Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET

US FDA approves Verrica's skin disease treatment

Jul 21, 2023, 4:35 PM EDT - 1 year ago

US FDA approves Verrica's skin disease treatment

Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

Jul 21, 2023, 4:24 PM EDT - 1 year ago

Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York

May 31, 2023, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York

Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference

May 10, 2023, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

May 9, 2023, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results